BIO.B vs. MTD, WAT, AVTR, ILMN, RVTY, BRKR, BIO, OLK, TXG, and LAB
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Mettler-Toledo International (MTD), Waters (WAT), Avantor (AVTR), Illumina (ILMN), Revvity (RVTY), Bruker (BRKR), Bio-Rad Laboratories (BIO), Olink Holding AB (publ) (OLK), 10x Genomics (TXG), and Standard BioTools (LAB). These companies are all part of the "analytical instruments" industry.
Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO.B) are both computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.
Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Mettler-Toledo International has a net margin of 20.55% compared to Mettler-Toledo International's net margin of -12.37%. Mettler-Toledo International's return on equity of 3.59% beat Bio-Rad Laboratories' return on equity.
Mettler-Toledo International has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Mettler-Toledo International received 241 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 57.60% of users gave Bio-Rad Laboratories an outperform vote while only 57.37% of users gave Mettler-Toledo International an outperform vote.
95.1% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 1.9% of Mettler-Toledo International shares are held by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Mettler-Toledo International presently has a consensus target price of $1,256.25, indicating a potential downside of 12.67%. Given Bio-Rad Laboratories' higher probable upside, equities research analysts plainly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.
In the previous week, Mettler-Toledo International had 15 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 16 mentions for Mettler-Toledo International and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.70 beat Mettler-Toledo International's score of 0.59 indicating that Mettler-Toledo International is being referred to more favorably in the media.
Summary
Mettler-Toledo International beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
